Discussing the Debate: Leukocyte-Rich Platelet-Rich Plasma Versus Leukocyte-Poor Platelet-Rich Plasma.
leukocyte-poor prp
leukocyte-rich prp
leukocyte-rich vs. leukocyte-poor platelet-rich plasma
leukocytes
platelet-rich plasma (prp)
Journal
Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737
Informations de publication
Date de publication:
Apr 2024
Apr 2024
Historique:
accepted:
16
04
2024
medline:
17
5
2024
pubmed:
17
5
2024
entrez:
17
5
2024
Statut:
epublish
Résumé
This editorial touches on the persistent debate related to platelet-rich plasma (PRP) therapy. It focuses on the different approaches involving leukocyte-rich and leukocyte-poor PRP formulations of the PRP. It looks into the reasons behind these approaches, their potential effects on clinical practice, i.e., pros and cons, and the evidence supporting each method within the field of regenerative medicine. Examining these different views highlights the complexity of PRP therapy. It's important to proceed carefully, relying on evidence to enhance patient outcomes. Understanding the ongoing debates can help healthcare professionals make informed decisions. We need to consider various factors before implementing PRP therapy, ensuring it's done responsibly.
Identifiants
pubmed: 38756260
doi: 10.7759/cureus.58381
pmc: PMC11097227
doi:
Types de publication
Editorial
Langues
eng
Pagination
e58381Informations de copyright
Copyright © 2024, Yadav et al.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.